The evolving role of receptors as predictive biomarkers for metastatic breast cancer
- 3 December 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Review of Anticancer Therapy
- Vol. 19 (2) , 121-138
Abstract
Introduction: In breast cancer, estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) are essential biomarkers to predict response to endocrine and anti-HER2 therapies, respectively. In metastatic breast cancer, the use of these receptors and targeted therapies present additional challenges: temporal heterogeneity, together with limited sampling methodologies, hinders receptor status assessment, and the constant evolution of the disease invariably leads to resistance to treatment. Areas covered: This review summarizes the genomic abnormalities in ER and HER2, such as mutations, amplifications, translocations, and alternative splicing, emerging as novel biomarkers that provide an insight into underlying mechanisms of resistance and hold potential predictive value to inform treatment selection. We also describe how liquid biopsies for sampling of circulating markers and ultrasensitive detection technologies have emerged which complement ongoing efforts for biomarker discovery and analysis. Expert commentary: While evidence suggests that genomic aberrations in ER and HER2 could contribute to meeting the pressing need for better predictive biomarkers, efforts need to be made to standardize assessment methods and better understand the resistance mechanisms these markers denote. Taking advantage of emerging technologies, research in upcoming years should include prospective trials incorporating these predictors into the study design to validate their potential clinical value.Keywords
Funding Information
- Breast Cancer Now (2017MayPR896)
This publication has 236 references indexed in Scilit:
- HER2-targeted therapy in breast cancer: A systematic review of neoadjuvant trialsCancer Treatment Reviews, 2013
- Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)Breast Cancer Research and Treatment, 2013
- Does Breast Tumor Heterogeneity Necessitate Further Immunohistochemical Staining on Surgical Specimens?Journal of the American College of Surgeons, 2013
- The Life History of 21 Breast CancersCell, 2012
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trialThe Lancet Oncology, 2012
- Tumor Metastasis: Molecular Insights and Evolving ParadigmsCell, 2011
- Review: Incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancerEuropean Journal of Surgical Oncology, 2011
- Complex landscapes of somatic rearrangement in human breast cancer genomesNature, 2009
- Massively Parallel Sequencing: The Next Big Thing in Genetic MedicineThe American Journal of Human Genetics, 2009
- Molecular profiles of progesterone receptor loss in human breast tumorsBreast Cancer Research and Treatment, 2008